EU Orphan Law A 'Remarkable Success' But Approval Speed and Patient Access Still Poor
This article was originally published in SRA
While the 15-year old EU orphan drugs legislation has "significantly helped to accelerate the translation of science into therapies for patients with rare diseases", orphan drugs are still not being approved - or reaching the patients who need them- fast enough.
You may also be interested in...
The European Commission has proposed changes to the existing criteria used for determining whether a new medicinal product is similar to an already authorized orphan drug and, therefore, whether it can be accepted for evaluation and granted 10-year market exclusivity.
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.